Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE: IRX-2 in oral cavity cancer
NCT02609386Phase 2Completed
- Sponsor
- Brooklyn ImmunoTherapeutics, Inc.
- Start
- Jan 2016
- Primary completion
- Feb 2022
- Modality
- Cytokines & Interferons
- Countries
- 4
01
Overview
A Phase 2 trial of citoplurikin in squamous cell carcinoma of the oral cavity (OSCC), sponsored by Brooklyn ImmunoTherapeutics, Inc.. Started Jan 2016; status: completed.
02
Drugs
citoplurikin
03
Conditions
squamous cell carcinoma of the oral cavity (OSCC)
Beyond the preview
Go deeper on NCT02609386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609386.